Cui Xuejun

Shanghai Sundise Traditional Chinese Medicine Co., Ltd. is a pharmaceutical company dedicated to the modernization and internationalization of Traditional Chinese Medicine (TCM). The company focuses on developing evidence-based botanical drugs for chronic conditions, particularly in hepatology and orthopedics. Its flagship product, Fuzheng Huayu (FZHY), is a widely recognized treatment for liver fibrosis and has successfully completed Phase II clinical trials in the United States under FDA oversight. Sundise maintains strong research collaborations with the Shanghai University of Traditional Chinese Medicine, where key investigators like Professor Cui Xuejun lead clinical validation efforts for proprietary products such as the Qishe Pill and Juanbi Pill. The company is notable for its commitment to rigorous clinical standards and its efforts to bring traditional therapies to the global market.